Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · May 6, 2011
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
Deep sedation with propofol has been suggested necessary for successful performance of endoscopic retrograde cholangiopancreatography (ERCP).Airway obstruction, hypoventilation and hypoxemia occurs in deeply sedated patients with a high incidence of 12-30%.As a result of frequent hypoxemia events, deep sedation is associated with increased morbidity and mortality.Careful monitoring of vital signs and involving of anesthesia-trained personal are recommended for deeply sedated patients.Self-administration of propofol by the patient him- or herself (patient-controlled sedation, PCS)could be a ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • elective ERCP patients
- Exclusion Criteria:
- • allergy to propofol or opioid analgesics, drug addiction, inability to co-operate, ASA class greater than 3, or patient's refusal.
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, Uusimaa, Finland
Patients applied
Trial Officials
Reino Pöyhiä, MD,PhD
Study Director
Helsinki University Central Hospital, Department of Anesthesiology and Intensive Care
Maxim Mazanikov, MD
Principal Investigator
Helsinki University Central Hospital,Department of Anesthesiology and Intensive Care
Martti Färkkilä, MD,Professor
Principal Investigator
Helsinki University Central Hospital,Department of Medicine, Division of Gastroenterology
Leena Kylänpää, MD,PhD
Principal Investigator
Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery
Jorma Halttunen, MD,PhD
Principal Investigator
Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery
Outi Lindström, MD,PhD
Principal Investigator
Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery
Harri Mustonen, DSc
Principal Investigator
Helsinki University Central Hospital, Department of Surgery
Marianne Udd, MD,PhD
Principal Investigator
Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials